<SEC-DOCUMENT>0001171520-22-000253.txt : 20220421
<SEC-HEADER>0001171520-22-000253.hdr.sgml : 20220421
<ACCEPTANCE-DATETIME>20220421131124
ACCESSION NUMBER:		0001171520-22-000253
CONFORMED SUBMISSION TYPE:	DFAN14A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20220421
DATE AS OF CHANGE:		20220421

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CATALYST BIOSCIENCES, INC.
		CENTRAL INDEX KEY:			0001124105
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				562020050
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DFAN14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51173
		FILM NUMBER:		22840805

	BUSINESS ADDRESS:	
		STREET 1:		611 GATEWAY BLVD., SUITE 710
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		650-871-0761

	MAIL ADDRESS:	
		STREET 1:		611 GATEWAY BLVD., SUITE 710
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TARGACEPT INC
		DATE OF NAME CHANGE:	20000919

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SINGER JULIAN D.
		CENTRAL INDEX KEY:			0001628706

	FILING VALUES:
		FORM TYPE:		DFAN14A

	MAIL ADDRESS:	
		STREET 1:		2200 FLETCHER AVENUE
		STREET 2:		SUITE 501
		CITY:			FORT LEE
		STATE:			NJ
		ZIP:			07024
</SEC-HEADER>
<DOCUMENT>
<TYPE>DFAN14A
<SEQUENCE>1
<FILENAME>eps10185.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 13.5pt Times New Roman,serif; margin: 0; text-align: center"><B>UNITED STATES </B></P>

<P STYLE="font: 13.5pt Times New Roman,serif; margin: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>

<P STYLE="font: 12pt Times New Roman,serif; margin: 0; text-align: center"><B>Washington, DC 20549</B></P>

<P STYLE="font: 8pt Times New Roman,serif; margin: 0">&nbsp;</P>

<P STYLE="font: 16pt Times New Roman,serif; margin: 0; text-align: center"><B>SCHEDULE 14A </B></P>

<P STYLE="font: 6pt Times New Roman,serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 12pt Times New Roman,serif; margin: 0; text-align: center"><B>Proxy Statement Pursuant to Section 14(a) of the </B></P>

<P STYLE="font: 12pt Times New Roman,serif; margin: 0; text-align: center"><B>Securities Exchange Act of 1934</B></P>

<P STYLE="font: 12pt Times New Roman,serif; margin: 0; text-align: center"><B>(Amendment No. )</B></P>

<P STYLE="font: 12pt Arial,sans-serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman,serif; margin: 0 0 2pt">Filed by the Registrant&nbsp;&nbsp;&nbsp;&nbsp;&#9744;</P>

<P STYLE="font: 12pt Times New Roman,serif; margin: 0 0 2pt">Filed by a Party other than the Registrant&nbsp;&nbsp;&nbsp;&nbsp;&#9745;</P>

<P STYLE="font: 12pt Times New Roman,serif; margin: 0 0 2pt">Check the appropriate box:</P>

<P STYLE="font: 12pt Times New Roman,serif; margin: 0 0 2pt">&#9744;&nbsp;&nbsp;&nbsp;&nbsp;Preliminary Proxy
Statement</P>

<P STYLE="font: 12pt Times New Roman,serif; margin: 0 0 2pt">&#9744;&nbsp;&nbsp;&nbsp;&nbsp;Confidential, For
Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</P>

<P STYLE="font: 12pt Times New Roman,serif; margin: 0 0 2pt">&#9744;&nbsp;&nbsp;&nbsp;&nbsp;Definitive Proxy Statement</P>

<P STYLE="font: 12pt Times New Roman,serif; margin: 0 0 2pt">&#9744;&nbsp;&nbsp;&nbsp;&nbsp;Definitive Additional
Materials</P>

<P STYLE="font: 12pt Times New Roman,serif; margin: 0 0 2pt">&#9745;&nbsp;&nbsp;&nbsp;&nbsp;Soliciting Material
Pursuant to &sect;240.14a-12</P>

<P STYLE="font: 12pt Times New Roman,serif; margin: 0 0 2pt">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman,serif; margin: 0; text-align: center"><B>CATALYST BIOSCIENCES, INC.</B></P>

<P STYLE="font: 12pt Times New Roman,serif; margin: 0; text-align: center"><B>(Name of Registrant as Specified in Its Charter)</B></P>

<P STYLE="font: 12pt Times New Roman,serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 14pt Times New Roman,serif; margin: 0; text-align: center"><B>JDS1, LLC</B></P>

<P STYLE="font: 14pt Times New Roman,serif; margin: 0; text-align: center"><B>CCUR HOLDINGS, INC.</B></P>

<P STYLE="font: 14pt Times New Roman,serif; margin: 0; text-align: center"><B>CIDM II, LLC</B></P>

<P STYLE="font: 14pt Times New Roman,serif; margin: 0; text-align: center"><B>JULIAN D. SINGER</B></P>

<P STYLE="font: 14pt Times New Roman,serif; margin: 0; text-align: center"><B>DAVID S. OROS</B></P>

<P STYLE="font: 14pt Times New Roman,serif; margin: 0; text-align: center"><B>SHELLY C. LOMBARD</B></P>

<P STYLE="font: 14pt Times New Roman,serif; margin: 0; text-align: center"><B>MATTHEW STECKER</B></P>

<P STYLE="font: 14pt Times New Roman,serif; margin: 0; text-align: center"><B>IGOR VOLSHTEYN</B></P>

<P STYLE="font: 12pt Times New Roman,serif; margin: 0; text-align: center"><B>(Name of Person(s) Filing Proxy Statement, if Other Than
the Registrant)</B></P>

<P STYLE="font: 12pt Times New Roman,serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman,serif; margin: 0">Payment of Filing Fee (Check the appropriate box):</P>

<P STYLE="font: 12pt Arial,sans-serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; font: 12pt Times New Roman,serif">&#9745;</TD>
    <TD>
    <P STYLE="font: 12pt Times New Roman,serif; margin: 0; text-align: justify">No fee required</P>
    <P STYLE="font: 12pt Arial,sans-serif; margin: 0; text-align: justify">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 12pt Times New Roman,serif">&#9744;</TD>
    <TD>
    <P STYLE="font: 12pt Times New Roman,serif; margin: 0">Fee paid previously with preliminary materials</P>
    <P STYLE="font: 12pt Arial,sans-serif; margin: 0">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 12pt Times New Roman,serif">&#9744;</TD>
    <TD STYLE="font: 12pt Times New Roman,serif">Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11</TD></TR>
  </TABLE>

<P STYLE="font: 12pt Times New Roman,serif; margin: 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 2pt; border-bottom: rgb(98,145,178) 2pt solid"></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->


<P STYLE="font: 11pt Times New Roman,serif; margin: 0 0 12pt; text-align: justify">JDS1, LLC, CCUR Holdings, Inc., CIDM II, LLC, Julian
D. Singer, David S. Oros, Shelly C. Lombard, Matthew Stecker, and Igor Volshteyn (collectively, &ldquo;<U>JDS1</U>&rdquo;), are filing
this Schedule 14A with the U.S. Securities and Exchange Commission (&ldquo;<U>SEC</U>&rdquo;) in connection with JDS1&rsquo;s plans to
solicit proxies from the stockholders of Catalyst Biosciences, Inc., a Delaware Corporation (the &ldquo;<U>Company</U>&rdquo;), in connection
with the Company&rsquo;s 2022 Annual Meeting of Stockholders, any special meeting held in lieu thereof, and at any and all adjournments
or postponements thereof (the &ldquo;<U>2022 Annual Meeting</U>&rdquo;).</P>

<P STYLE="font: 11pt Times New Roman,serif; margin: 0 0 12pt; text-align: justify"><B>Schedule 13D Amendment No. 10 Filed on April 21,
2022</B></P>

<P STYLE="font: 11pt Times New Roman,serif; margin: 0 0 12pt; text-align: justify">On April 21, 2022, JDS1 filed Amendment No. 10 to its
Schedule 13D with respect to the Company (the &ldquo;<U>Schedule 13D/A</U>&rdquo;). The following disclosure was included in Item 4 of
the Schedule 13D/A and is being included in this Schedule 14A because such disclosure may be deemed&nbsp;to be solicitation material in
connection with JDS1&rsquo;s plans to solicit proxies from the Company&rsquo;s stockholders for use at the 2022 Annual Meeting:</P>

<P STYLE="font: 11pt Times New Roman,serif; margin: 0 0 12pt; text-align: justify"><I>&ldquo;Item 4 is hereby amended to add the following:</I></P>

<P STYLE="font: 11pt Times New Roman,serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in; background-color: white"><I>As
previously disclosed, on March 15, 2022, JDS1, acting pursuant to Section 220 of the Delaware General Corporation Law, delivered a letter
to the Issuer demanding the right to inspect certain books, records, and documents of the Issuer and to make and/or receive copies or
extracts therefrom (the &ldquo;<U>JDS1 Inspection Demand</U>&rdquo;). The books, records, and documents that JDS1 is seeking to inspect
pursuant to the JDS1 Inspection Demand relate, in large part, to the record and beneficial ownership of the outstanding Shares. As noted
in the JDS1 Inspection Demand, the purpose of the demand is to enable JDS1 to communicate with, and solicit proxies from, the other stockholders
of the Issuer with respect to matters relating to their mutual interests as stockholders of the Issuer, including, but not limited to,
the composition and structure of the Board of Directors of the Issuer (the &ldquo;<U>Board</U>&rdquo;), the election of directors at the
Issuer&rsquo;s 2022 annual meeting of stockholders (the &ldquo;<U>2022 Annual Meeting</U>&rdquo;), any other proposals that JDS1 may submit
for consideration at the 2022 Annual Meeting, and any other matters that may properly come before the 2022 Annual Meeting.</I></P>

<P STYLE="font: 11pt Times New Roman,serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in; background-color: white"><I>As
of April 20, 2022, more than a month after having delivered the JDS1 Inspection Demand to the Issuer, JDS1 has not received any documents
from the Issuer in response to the JDS1 Inspection Demand and has not received any firm commitment from the Issuer as to which of the
documents requested by JDS1 would be provided or when any of the documents requested by JDS1 would be provided. Accordingly, on April
20, 2022, JDS1 filed a complaint against the Issuer in the Delaware Court of Chancery seeking to compel the Issuer to produce the documents
responsive to the JDS1 Inspection Demand and requesting that the Delaware Court of Chancery order the Issuer to pay reasonable attorneys&rsquo;
fees and expenses incurred by JDS1 in connection with the JDS1 Inspection Demand and the related litigation.</I></P>

<P STYLE="font: 11pt Times New Roman,serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in; background-color: white"><I>JDS1
continues to take the necessary steps to prepare for a proxy contest in connection with the 2022 Annual Meeting, JDS1 continues to believe
that, given the precipitous decline in the per share price of the Common Stock over the past year, the Board is in urgent need of fresh
stockholder representation and that the three nominees JDS1 has proposed for election to the Board at the 2022 Annual Meeting, Shelly
C. Lombard, Matthew Stecker, and Igor Volshteyn, can help the Board to explore opportunities to unlock stockholder value. As of the close
of business on April 20, 2022, the Common Stock closed at a price of $0.53 per share, which represents an approximately 89.42% decline
from the Common Stock&rsquo;s closing price of $4.98 per share on April 21, 2021. In addition, the Common Stock has spent more than thirty
(30) consecutive trading days below $1.00, the latter condition subjecting the Issuer to the risk of being delisted by Nasdaq. </I></P>

<P STYLE="font: 11pt Times New Roman,serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in; background-color: white"><I>Except
as set forth in this Schedule 13D or such as would occur upon or in connection with completion of, or following, any of the actions discussed
in this Schedule 13D, no Reporting Person has any present plan or proposal which would relate to or result in any of the matters set forth
in subparagraphs (a) - (j) of Item 4 of Schedule 13D. The Reporting Persons intend to review their investment in the Issuer on a continuing
basis. Depending on various factors including, without limitation, the Issuer&rsquo;s financial position and strategic direction, actions
taken by the Board, the price levels of the Shares, other investment opportunities available to the Reporting Persons, conditions in the
securities markets and general economic and industry conditions, the Reporting Persons may in the future take such actions with respect
to their investment in the Issuer as they deem appropriate including, without limitation, engaging in communications with management and/or
the Board, engaging in communications with one or more stockholders of the Issuer and others about the Issuer and the Reporting Persons&rsquo;
investment, making suggestions and/or proposals concerning the Issuer&rsquo;s capitalization, ownership structure, operations, prospects,
business and financial strategies, strategic transactions, assets and liabilities, business and financing alternatives, the structure
and composition of the Board, and such other matters as the Reporting Persons may deem relevant to their investment in the Issuer, selling
some or all of their Shares in the open market or otherwise, engaging in short selling of or any hedging or similar transaction with respect
to the Shares, acquiring additional Shares and/or other equity, debt, notes, other securities, or derivative or other instruments that
are based upon or relate to the value of securities of the Issuer, or changing their intention with respect to any and all matters referred
to in Item 4.&rdquo;</I></P>

<P STYLE="font: 11pt Times New Roman,serif; margin: 0 0 8pt"><B>Important Additional Information and Certain Information Concerning the
Participants</B></P>

<P STYLE="font: 11pt Times New Roman,serif; margin: 0 0 12pt; text-align: justify">JDS1 intends to file a preliminary proxy statement
and accompanying proxy card with the SEC to be used to solicit proxies from the Company&rsquo;s stockholders in connection with the 2022
Annual Meeting to have stockholders elect three director nominees to the Company&rsquo;s Board of Directors (the &ldquo;<U>Board</U>&rdquo;)
and approve a non-binding proposal requesting that the Board take the necessary steps to declassify the Board (in a manner that does not
affect the unexpired terms of the previously elected directors) so that all directors are elected on an annual basis commencing at the
next annual meeting of stockholders after the 2022 Annual Meeting.</P>

<P STYLE="font: 11pt Times New Roman,serif; margin: 0 0 12pt; text-align: justify">JDS1 STRONGLY ADVISES ALL STOCKHOLDERS OF THE COMPANY
TO READ THE PROXY STATEMENT AND OTHER PROXY MATERIALS AS THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. SUCH PROXY
MATERIALS WILL BE AVAILABLE AT NO CHARGE ON THE SEC'S WEB SITE AT&nbsp;<U>HTTPS://WWW.SEC.GOV</U>.</P>

<P STYLE="font: 11pt Times New Roman,serif; margin: 0 0 12pt; text-align: justify">The participants in the proxy solicitation are anticipated
to be JDS1, LLC, a Delaware limited liability company, CCUR Holdings, Inc., a Delaware corporation, CIDM II, LLC, a Delaware limited liability
company, Julian D. Singer, David S. Oros, Shelly C. Lombard, Matthew Stecker, and Igor Volshteyn.</P>

<P STYLE="font: 11pt Times New Roman,serif; margin: 0 0 12pt; text-align: justify">As of the date hereof, JDS1, LLC directly beneficially
owns 780,432 shares of Common Stock, par value $0.001 per share, of the Company (the &ldquo;<U>Common Stock</U>&rdquo;), including 500
shares of Common Stock held in record name. As of the date hereof, CCUR Holdings, Inc. directly beneficially owns 532,100 shares of Common
Stock. JDS1, LLC, as an affiliate of CCUR Holdings, Inc., may also be deemed to be the beneficial owner of the 532,100 shares of Common
Stock held by CCUR Holdings, Inc. As of the date hereof, CIDM II, LLC does not directly own any shares of Common Stock, but, as the asset
manager to CCUR Holdings, Inc., may be deemed the beneficial owner of the 532,100 shares of Common Stock beneficially owned by CCUR Holdings,
Inc. As of the date hereof, Mr. Singer does not directly own any shares of Common Stock, but may be deemed to have beneficial ownership
of the Common Stock as a result of being the managing member of each of JDS1 and CIDM II, LLC and an affiliate of CCUR Holdings, Inc.
Accordingly, Mr. Singer may be deemed to beneficially own (i) the 780,432 shares of Common Stock directly beneficially owned by JDS1,
LLC, and (ii) the 532,100 shares of Common Stock directly beneficially owned by CCUR Holdings, Inc. As of the date hereof, Mr. Oros directly
beneficially owns 338,600 shares of Common Stock. As of the date hereof, none of Ms. Lombard and Messrs. Stecker and Volshteyn beneficially
owned any shares of Common Stock.</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
